ANIMALCARE GROUP PLC (ANCR) — Investment Research Note

Executive summary

Animalcare is an AIM-listed international veterinary pharmaceuticals company operating in seven European countries plus Australia/New Zealand, with a portfolio of ~165 branded animal health products spanning Companion, Production and Equine animals 2026-05-06 final results. Across the 5-year period, revenue grew from £70.7m (FY23) to £89.1m (FY25), with FY25 underlying EBITDA rising 52.6% to £17.7m, supercharged by the January 2025 Randlab acquisition 2026-05-06 final results. The single most important point for valuation today is that the stock is subject to a recommended cash offer at 336p per share from Charterhouse Capital Partners (announced 16 April 2026), with trading temporarily suspended on 30 July 2026 pending an announcement — the market price of 335p leaves essentially no upside to the offer 2026-04-16 recommended acquisition; 2026-07-30 suspension.

Fair value estimate

• Fair value range: 336p – 336p per share (implied market cap £232.1m fully diluted, or £235.2m per the Bidco's stated valuation of issued & to-be-issued capital) 2026-04-16.
• Methodology: Deal-anchored. With a firm 336p cash offer recommended by the Board, backed by irrevocable undertakings representing 41.7% of ISC (23.3% from directors + 18.4% from Harwood Capital), and completion expected Q2/Q3 2026, the stock price is anchored to the deal price. Independent DCF/multiple work is moot in this context.
• Sanity check (multiples): At the offer, EV of ~£244.3m equates to ~13.8x FY25 underlying EBITDA of £17.7m — a full but not egregious multiple for an integrated animal-health platform with double-digit growth in flagship brands. Animalcare's own Board flagged that the offer "fairly recognises Animalcare's future growth prospects" and that reaching the internally targeted ~£150m revenue / ~25% EBITDA margin by 2030 "carries significant risks" 2026-04-16.
• Comparison to current market cap of £230.3m: implied upside ~0.3% to the 336p offer; nil incremental upside from here.

Sector context

• Sector classification confirmed: Health Care (ICB Super-Sector). Specifically, animal health pharmaceuticals — a growth sub-sector with attractive structural tailwinds (rising pet ownership, humanisation of pets, biologics innovation).
• Quality/growth/leverage profile vs peers: Below the growth and margin profile of large animal-health peers such as Zoetis (ZTS), Elanco (ELAN), Dechra (was DPH — taken private in 2024). Animalcare is a sub-scale European specialist with a ~20% EBITDA margin trajectory vs ~30%+ for tier-1 peers, but with a fortress-adjacent balance sheet (0.7x leverage) and improving cash conversion. It is now on the path Dechra took: attracting private equity at a control premium.
• Peers: Zoetis (US), Elanco (US), Virbac (France), Vetoquinol (France), historically Dechra Pharmaceuticals (UK).

Investment thesis (3 bullets)

1. Deal certainty at 336p with c.42% irrevocable support — Charterhouse's recommended offer is backed by binding undertakings from directors (23.3%) and Harwood Capital (18.4%); scheme of arrangement targeted for Q2/Q3 2026 completion 2026-04-16. At the current 335p price this is essentially a cash-equivalent position with ~2-3 month duration risk.
2. Underlying trading momentum supports the offer economics — FY25 revenue +20% to £89.1m, underlying EBITDA +52.6% to £17.7m, Randlab integration ahead of expectations, flagship brands (Daxocox +23%, Plaqtiv+ +42%, Orozyme +30%) still growing at double digits 2026-05-06.
3. Downside protection is exceptional given the deal backdrop — recommended cash offer with committed financing, low leverage (0.7x), no antitrust risk of note, only material condition is Australian FIRB approval which is a formality 2026-04-16.

Key risks (3 bullets)

1. Deal failure risk — although low, if FIRB conditions or shareholder approval unexpectedly fail, the share price would revert to a pre-bid level (247p on 15 April 2026, a ~26% downside from 335p) 2026-04-16.
2. Suspension of trading on 30 July 2026 — the trading halt on the last practicable day suggests an imminent announcement (likely deal completion or scheme sanction), but the nature of the announcement is not yet known and could theoretically be adverse 2026-07-30 suspension.
3. R&D pipeline execution and future growth are now Charterhouse's problem, not the public shareholder's — the Board explicitly acknowledged that delivering 2030 targets "would require a sustained period of investment and execution" better suited to private ownership; standalone valuation would be lower than 336p on a conservative case 2026-05-06 Chair's statement; 2026-04-16.

Operating leverage

Animalcare has moderate operating leverage typical of a specialty pharma commercial platform. Gross margin expanded 320bps to 58.8% in FY25, and underlying EBITDA margin improved 500bps to 20.6% (before R&D), demonstrating that incremental revenue drops through at attractive rates when portfolio mix skews to owned brands (Randlab standalone gross margin was 72.9%, EBITDA margin 47.6%) 2026-05-06. Central overheads scale sub-linearly with revenue: FY25 underlying overheads of £34.0m on £89.1m revenue vs £29.7m on £74.2m in FY24 (14% overhead growth on 20% revenue growth). A 10-20% revenue beat above current expectations would likely deliver ~30-50% incremental EBITDA at existing gross margins, so operating leverage is real but not extreme — this is a commercial pharma business, not a pure software platform. The Board's stated 2030 ambition of ~£150m revenue at ~25% EBITDA margin implies significant further margin expansion, but requires sustained R&D investment (targeted at ~5% of revenue vs 2.8% historically) that the market did not fully back — hence the private-equity exit 2026-04-16; 2026-05-06.

Value-trap signals

None identified. The company is being acquired at a 36% premium to the pre-bid closing price. Financials are clean, cash conversion consistent (~80% guidance range), balance sheet strong (0.7x leverage), and the going-concern audit note flags only the deal-related uncertainty rather than any operational fragility 2026-05-06 note 3.

Earnings vs. expectations

• FY23: revenue £74.4m, underlying EBITDA £13.3m — Board said "in line with market expectations" 2024-01-25 trading update; 2024-04-09 prelims.
• FY24: revenue £74.2m (declining vs FY23 restated basis excluding Identicare from £70.7m — in line), underlying EBITDA £11.6m from continuing operations, "in line with market expectations" 2025-01-23 trading update; 2025-04-29 prelims.
• H1 2025: revenue £43.8m (+18.5%), underlying EBITDA £9.2m (+39.5%), "in line with expectations" 2025-09-30 interims.
• FY25: revenue £89.1m, underlying EBITDA £17.7m — Board's January 2026 guidance implied consensus of £89.2m / £17.6m; delivered essentially in line 2026-01-22 trading update; 2026-05-06 final results.

Pattern: consistent in-line to modest-beat delivery over the 5-year period, with no profit warnings. A slight positive lean overall. FY25 was a beat on Randlab contribution vs initial acquisition expectations.

Conviction

Conviction: 5 — very high.

The fair value call here is unusually easy: there is a live, recommended, cash offer at 336p supported by 41.7% of the share capital via irrevocable undertakings, with financing committed and only routine regulatory conditions outstanding. The stock trades at 335p. Anchoring factors: (1) binding scheme of arrangement documentation; (2) FY25 results validate the deal price; (3) trading suspension on 30 July 2026 signals imminent completion news. Limiting factor: I cannot verify the reason for the trading suspension after 30 July 2026, so there is a small tail risk of an unexpected announcement.